CUAMC
CBAY

China Universal Asset Management Company’s Cymabay Therapeutics CBAY Stock Holding History

China Universal Asset Management Company’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,114
Closed -$310K – 451
2023
Q4 		$310K Buy
13,114
+10,598
+421% +$189K 0.06% 174
2023
Q3 		$37.5K Buy
2,516
+1,238
+97% +$16.4K 0.01% 248
2023
Q2 		$14K Sell
1,278
-4
-0.3% -$37 ﹤0.01% 299
2023
Q1 		$11.2K Buy
1,282
+422
+49% +$3.38K ﹤0.01% 282
2022
Q4 		$5.39K Buy
860
+67
+8% +$255 ﹤0.01% 290
2022
Q3 		$3K Buy
+793
New +$2.85K ﹤0.01% 342

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

China Universal Asset Management Company's CBAY Position: Q1 2024 in Review

China Universal Asset Management Company sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 13,114 shares — an estimated $310K sold.

China Universal Asset Management Company first reported a position in CBAY in Q3 2022 and held it in 6 quarters. The position peaked at $310K in Q4 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • China Universal Asset Management Company reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • China Universal Asset Management Company sold 13,114 Cymabay Therapeutics shares in Q1 2024, an estimated $310K.
  • China Universal Asset Management Company first reported a position in Cymabay Therapeutics in Q3 2022 and held it in 6 quarters.
  • China Universal Asset Management Company's Cymabay Therapeutics position peaked at $310K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on China Universal Asset Management Company's 13F filing for Q1 2024, filed 29 Apr 2024.